drugset / Trial / NCT01587716
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2339345.
RandomizedParallel-groupDouble-blindTreatment
Summary
This is a study of the sodium channel inhibitor, GSK2339345. Cohort 1 will assess the safety, tolerability and PK of single ascending doses of GSK2339345 administered via an aqueous droplet inhaler in healthy subjects. Cohort 2 will assess the safety, tolerability, and PK of repeat doses of GSK2339345 administered four times a day for two consecutive days via an aqueous droplet inhaler.
Timeline
- Start
- 2012-04-23
- Primary completion
- 2012-07-30
- Completion
- 2012-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GSK2339345 | Small molecule | 250 ug | Other |
| Subject | GSK2339345 | Small molecule | 1000 ug | Other |
| Subject | GSK2339345 | Small molecule | 2000 ug | Other |
Indications
No indication recorded.